

DATE:	2022 July 27
TO:	Edmonton Zone, North Zone, Central Zone (excluding Hanna, Drumheller, and Three Hills) Family Physicians, Obstetrics/Gynecology, Maternal Fetal Medicine Clinic
FROM:	Alberta Precision Laboratories (APL) – North Sector, University of Alberta Hospital
RE:	Delays in Reporting First Trimester Prenatal Risk Assessment

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Due to instrumentation problems and staffing shortages, health providers may notice a delay in reporting of first trimester prenatal risk assessment performed at the University of Alberta Hospital.

How this will impact you

- The Biochemical Genetics Laboratory in Edmonton performs the biochemical testing, integrates with the nuchal translucency ultrasound, and issues a risk report for aneuploidy (trisomy 21, 18, 13) for pregnant women in the Edmonton, North and Central zones.
- Providers may notice a delay in reporting of first trimester prenatal risk assessment performed at the University of Alberta Hospital due to instrumentation problems.

Action Required

- None

Inquiries and feedback may be directed to

- Miranda Brun, PhD, Clinical Biochemist, University of Alberta Hospital, 780-722-4123, Miranda.Brun2@albertaprecisionlabs.ca

This bulletin has been reviewed and approved by

- Dr. Kareena Schnabl, Section Chief Biochemistry, Alberta Precision Laboratories, North Sector
- Dr. Dennis Bulman, Medical/Scientific Director, Genetics and Genomics, APL
- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), APL